BioCentury
ARTICLE | Clinical News

Gevokizumab gets out of hand

March 5, 2014 1:08 AM UTC

Xoma Corp. (NASDAQOMA) fell $1.94 (21%) to $7.50 in early after-hours trading on Tuesday after the company said after market close that it does not intend to start Phase III testing of gevokizumab ( XOMA 052) for the "broad indication" of osteoarthritis (OA) of the hand, but said it will review data for subgroup responses. The move came after the company said top-line data from the Phase II Study 160 and Study 162 trials evaluating once-monthly subcutaneous gevokizumab to treat active inflammatory, erosive OA of the hand "were not positive."

Gevokizumab is also in the Phase III EYEGUARD program to treat non-infectious uveitis and Behcet's uveitis and in Phase II testing to treat pyoderma gangrenosum. ...